Collecting duct carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:247203C64
Who is this for?
Show terms as
2Active trials13Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Collecting duct carcinoma (CDC), also known as Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma that arises from the epithelial cells lining the collecting ducts of the kidney. It accounts for less than 1-2% of all renal cell carcinomas. The tumor originates in the medullary region of the kidney and tends to grow rapidly, often presenting at an advanced stage with local invasion or distant metastases. The disease primarily affects the urinary system but can metastasize to the lungs, lymph nodes, liver, bone, and adrenal glands. Key symptoms include flank pain, hematuria (blood in the urine), a palpable abdominal mass, weight loss, fatigue, and fever. Many patients present with locally advanced or metastatic disease at the time of diagnosis, which contributes to the poor prognosis associated with this tumor type. Imaging studies such as CT scans typically reveal an infiltrative renal mass centered in the medulla, and definitive diagnosis requires histopathological examination showing characteristic tubulopapillary architecture with high-grade cytology and a desmoplastic stromal reaction. The treatment landscape for collecting duct carcinoma remains challenging due to its rarity and aggressive behavior. Radical nephrectomy (surgical removal of the affected kidney) is the primary treatment for localized disease. However, CDC is generally resistant to conventional therapies used for other renal cell carcinoma subtypes, including targeted therapies such as tyrosine kinase inhibitors. Platinum-based chemotherapy regimens (similar to those used for urothelial carcinomas) have shown some activity and are often considered for metastatic disease. More recently, immune checkpoint inhibitors have been explored, though evidence remains limited. Overall prognosis is poor, with median survival for metastatic disease often reported as less than one to two years.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
May 2025Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Giuseppe Procopio — PHASE2

TrialRECRUITING
Feb 2024Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Peking University Cancer Hospital & Institute — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Collecting duct carcinoma.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Phase 22 trials
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Phase 2
Actively Recruiting
PI: Xinan Sheng, MD. (Peking University Cancer Hospital & Institute) · Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality · Age: 1880 yrs
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Phase 2
Actively Recruiting
PI: Giuseppe Procopio, MD (Fondazione IRCCS Istituto Nazionale dei Tumori di ) · Sites: Milan · Age: 1899 yrs

Specialists

13 foundView all specialists →
GM
Giuseppe Procopio, MD
RAHWAY, NJ
Specialist
PI on 8 active trials1 Collecting duct carcinoma publication
NM
Nizar M. Tannir, MD
HOUSTON, TX
Specialist
PI on 3 active trials
AA
Andrea B Apolo
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 4 active trials
DM
Darren Feldman, MD
NEW YORK, NY
Specialist
PI on 8 active trials
CD
Constance THIBAULT, Dr
Specialist
PI on 1 active trial
AM
Abbot R. Laptook, MD
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 11 active trials1 Collecting duct carcinoma publication
XM
Xinan Sheng, MD.
Specialist
PI on 1 active trial
RM
Rana R McKay
SAN DIEGO, CA
Specialist
PI on 1 active trial14 Collecting duct carcinoma publications
JM
Jun Guo, MD,PHD
Specialist
PI on 2 active trials
AM
Ahmad A. Tarhini, MD, MS
PITTSBURGH, PA
Specialist
PI on 2 active trials
FB
Filippo De Braud
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Collecting duct carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Collecting duct carcinomaForum →

No community posts yet. Be the first to share your experience with Collecting duct carcinoma.

Start the conversation →

Latest news about Collecting duct carcinoma

1 articles
Clinical trialCLINICALTRIALSMar 26, 2026
Trial Now Recruiting: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)
Researchers are testing whether combining three cancer drugs—nivolumab, ipilimumab, and cabozantinib—can help treat rare cancers of the bladder, kidney, prostat
See all news about Collecting duct carcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Collecting duct carcinoma

What is Collecting duct carcinoma?

Collecting duct carcinoma (CDC), also known as Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma that arises from the epithelial cells lining the collecting ducts of the kidney. It accounts for less than 1-2% of all renal cell carcinomas. The tumor originates in the medullary region of the kidney and tends to grow rapidly, often presenting at an advanced stage with local invasion or distant metastases. The disease primarily affects the urinary system but can metastasize to the lungs, lymph nodes, liver, bone, and adrenal glands. Key symptoms include flank pain,

How is Collecting duct carcinoma inherited?

Collecting duct carcinoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Collecting duct carcinoma typically begin?

Typical onset of Collecting duct carcinoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Collecting duct carcinoma?

Yes — 2 recruiting clinical trials are currently listed for Collecting duct carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Collecting duct carcinoma?

13 specialists and care centers treating Collecting duct carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.